Company: CRNX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001658247-25-000019
Chunk: 105

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 2
Chunk 105
---
 8,642 134 %33,982 15,595 18,387 118 %Early research and development programs9,264 6,598 2,666 40 %25,928 18,497 7,431 40 %Personnel expenses26,062 17,617 8,445 48 %76,827 50,489 26,338 52 %Stock-based compensation13,003 10,556 2,447 23 %37,921 29,612 8,309 28 %Other8,240 7,015 1,225 17 %21,795 19,687 2,108 11 %Total research and development expenses$90,464 $61,905 $28,559 46 %$247,005 $173,590 $73,415 42 %

The increase in research and development programs for the three and nine months ended September 30, 2025 as compared to the prior year periods was primarily due to clinical, manufacturing, and outside services costs associated with paltusotine for the treatment of carcinoid syndrome and atumelnant, preclinical, clinical, manufacturing, and outside services costs for early research and development programs, and increase in headcount and other increases to support the overall increased activities in various programs.

Selling, general and administrative expenses.     The increase of $26.4 million and $66.1 million in selling, general and administrative expenses during the three and nine months ended September 30, 2025, respectively, compared to the prior year periods was primarily due to the increase in personnel expenses of $10.2 million (including $2.1 million of stock-based compensation expense) and $29.1 million (including $10.4 million of stock-based compensation expense) for the 

24

Table of Contents

three and nine months ended September 30, 2025, respectively, when compared to the same periods in 2024. The remainder of the increase is primarily attributable to an increase in outside services of $12.0 million and $29.0 million for the three and nine months ended September 30, 2025, respectively, as compared to the prior year periods. These increases are attributable to the increase in headcount and increase in selling and other general and administrative costs to support our overall growth and the commercial launch of PALSONIFY.